{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:53:28Z","timestamp":1787849608688,"version":"build-2784847793"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T00:00:00Z","timestamp":1727654400000},"content-version":"vor","delay-in-days":273,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.14283\/jpad.2024.2","type":"journal-article","created":{"date-parts":[[2024,1,3]],"date-time":"2024-01-03T08:24:16Z","timestamp":1704270256000},"page":"65-70","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Phase 1\/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer's Disease"],"prefix":"10.1016","volume":"11","author":[{"given":"Marc","family":"Cantillon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Andreasen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Prins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14283\/jpad.2024.2_bib1","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1039\/C6CS00731G","article-title":"Towards an understanding of amyloid-\u03b2 oligomers: characterization, toxicity mechanisms, and inhibitors","volume":"46","author":"Lee","year":"2017","journal-title":"Chem Soc Rev"},{"key":"10.14283\/jpad.2024.2_bib2","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1093\/brain\/awt362","article-title":"Biochemical stages of amyloid-\u03b2 peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer's disease","volume":"137","author":"Rijal Upadhaya","year":"2014","journal-title":"Brain"},{"key":"10.14283\/jpad.2024.2_bib3","doi-asserted-by":"crossref","first-page":"a006189","DOI":"10.1101\/cshperspect.a006189","article-title":"Neuropathological alterations in Alzheimer disease","volume":"1","author":"Serrano-Pozo","year":"2011","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.14283\/jpad.2024.2_bib4","doi-asserted-by":"crossref","first-page":"2884","DOI":"10.1523\/JNEUROSCI.1675-13.2014","article-title":"A sensitive a\u03b2 oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid","volume":"34","author":"Savage","year":"2014","journal-title":"J Neurosci"},{"key":"10.14283\/jpad.2024.2_bib5","series-title":"Dementia in Clinical Practice. 2009","author":"Giannakopoulos","year":"2009"},{"key":"10.14283\/jpad.2024.2_bib6","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1038\/nm1782","article-title":"Amyloid-\u03b2 protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory","volume":"14","author":"Shankar","year":"2008","journal-title":"Nat Med"},{"issue":"12","key":"10.14283\/jpad.2024.2_bib7","doi-asserted-by":"crossref","first-page":"4833","DOI":"10.1523\/JNEUROSCI.22-12-04833.2002","article-title":"A novel function of monomeric amyloid \u03b2-protein serving as an antioxidant molecule against metal-induced oxidative damage","volume":"22","author":"Zou","year":"2002","journal-title":"J Neuroscience"},{"key":"10.14283\/jpad.2024.2_bib8","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1001\/archneur.59.9.1381","article-title":"Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease","volume":"59","author":"Fukumoto","year":"2002","journal-title":"Arch Neurol"},{"key":"10.14283\/jpad.2024.2_bib9","doi-asserted-by":"crossref","first-page":"784698","DOI":"10.1155\/2011\/784698","article-title":"pple Procyanidins Suppress Amyloid \u03b2-Protein Aggregation","volume":"2011","author":"Toda","year":"2011","journal-title":"Biochem Res Int"},{"key":"10.14283\/jpad.2024.2_bib10","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1212\/WNL.0b013e3181c67808","article-title":"A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease","volume":"73","author":"Salloway","year":"2009","journal-title":"Neurology"},{"key":"10.14283\/jpad.2024.2_bib11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1001\/archneurol.2011.1538","article-title":"Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab","volume":"69","author":"Ostrowitzki","year":"2012","journal-title":"Arch Neurol"},{"key":"10.14283\/jpad.2024.2_bib12","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/j.jalz.2012.11.010","article-title":"Vascular alterations in PDAPP mice after anti-A\u03b2 immunotherapy: Implications for amyloid-related imaging abnormalities","volume":"9","author":"Zago","year":"2013","journal-title":"Alzheimers Dement"},{"issue":"80","key":"10.14283\/jpad.2024.2_bib14","volume":"13","year":"2021","journal-title":"Alz Res Therapy"},{"key":"10.14283\/jpad.2024.2_bib15","author":"Biogen"},{"key":"10.14283\/jpad.2024.2_bib16","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa2100708","article-title":"Donanemab in early Alzheimer's disease","volume":"384","author":"Mintun","year":"2021","journal-title":"N Engl J Med"},{"key":"10.14283\/jpad.2024.2_bib17","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-017-0318-y","article-title":"A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease","volume":"9","author":"Ostrowitzki","year":"2017","journal-title":"Alz Res Therapy"},{"key":"10.14283\/jpad.2024.2_bib18","first-page":"46","article-title":"Phase 1 trial of a novel humanized anti-amyloid beta (A\u03b2) aggregates specific antibody KHK6640 in Alzheimer's disease","volume":"5","author":"Cantillon","year":"2018","journal-title":"J. Prevent. Alzheimer's Dis"},{"key":"10.14283\/jpad.2024.2_bib19","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","article-title":"The Clinical Dementia Rating (CDR)\u2014current version and scoring rules","volume":"43","author":"Morris","year":"1993","journal-title":"Neurology"},{"issue":"2","key":"10.14283\/jpad.2024.2_bib20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/gps.930060208","article-title":"The Cognitive Drug Research Computerized Assessment System for Demented Patients: A Validated Trial","volume":"6","author":"Simpson","year":"1991","journal-title":"Int J Geriatr Psychiatry"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724001092?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724001092?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T23:37:39Z","timestamp":1736465859000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724001092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S2274580724001092"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2024.2","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Phase 1\/2a Intravenous and Subcutaneous Oligomer-Specific Antibody KHK6640 in Mild to Moderate Alzheimer's Disease","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2024.2","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2023 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}